Fig. 6
IL-11 enhanced prostate cancer (PCa) progression and docetaxel resistance in vivo. A Representative image of subcutaneous tumours in the control, IL-11 knockdown, docetaxel-treated (Ctrl + DTX), and dual-treated (DTX + Sh IL-11) groups. B Histogram showing tumour weights in the control, IL-11 knockdown, Ctrl + DTX and DTX + Sh IL-11 groups after surgical dissection. C Growth of the tumours in the control, IL-11 knockdown, Ctrl + DTX and DTX + Sh IL-11 groups was measured every 3 days, and tumour growth curves were calculated. The mean ± standard deviation (SD) of the tumour volumes measured in 6 mice is shown. D Immunohistochemical staining showing IL-11 and Ki67 expression in tumours. E, F Histogram showing the H‐scores of Ki-67 and IL-11 in the control, IL-11 knockdown, Ctrl + DTX and DTX + Sh IL-11 groups. The error bars represent the standard deviations of values in each group (n = 6). G Pearson correlation analysis between IL-11 and Ki67 expression. H, I Comparative immunohistochemical analysis of IL-11 expression in docetaxel-resistant clinical prostate cancer tissues versus naive counterparts, as shown in representative images and quantified in a violin plot (n = 16)